Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells

Figure 3

PF-04691502 inhibits the PI3K/Akt/mTOR pathway in bladder cancer cells. (a) T-24 and 5637 cells were treated with the indicated doses of PF-04691502 for 24 (h) and the levels of specific proteins were measured using western blot. (b) T-24 and 5637 cells were transfected with an empty vector (EV) or a vector expressing myr-Akt (OV Akt) for 12 h; then, the cells were treated with or without PF-04691502 for another 24 h and the specific proteins were measured using western blots. (c) T-24 and 5637 cells were treated as indicated above, and cellular apoptosis was measured. (d) Cellular viabilities of the cells were measured. Data are representative of at least three independent experiments (; ).

(a)

(b)

(c)

(d)